Bevacizumab structure, CAS 216974-75-3

Bevacizumab

CAS Number216974-75-3

SynonymsLithium 4-{[2-(diethylamino)ethyl]carbamoyl}-2-iodobenzoate; Benzoic acid, 4-[[[2-(diethylamino)ethyl]amino]carbonyl]-2-iodo-, lithium salt (1:1)

Molecular FormulaC14H18ILiN2O3

Molecular Weight396.150

Purity

Density

Boiling Point

Melting Point

Flash Point

Appearanceliquid

EINECS

MSDSChineseEnglish

Symbol

Signal Word

Cat. No.: 2A-0202028 Purity:
Change View

Please Login or Create an Account to: See VlP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

Quality Control of [ 216974-75-3 ] SDS Specification MoL

Chemical & Physical Properties
CAS Number216974-75-3
Catalog No.2A-0202028
Chinese Name阿瓦斯丁
SynonymsLithium 4-{[2-(diethylamino)ethyl]carbamoyl}-2-iodobenzoate; Benzoic acid, 4-[[[2-(diethylamino)ethyl]amino]carbonyl]-2-iodo-, lithium salt (1:1)
Molecular FormulaC14H18ILiN2O3
Molecular Weight396.150
Appearanceliquid
Storage Condition-20℃, avoid light
ApplicationBevacizumab, a humanized vascular endothelial growth factor (VEGF) antibody, is a highly effective monoclonal antibody. Bevacizumab can be used in cancer research [1][2].
MDL NumberMFCD00051787
NACRES CodeNA.24
UNSPSC41116107
MSDSmsds/59492_1_216974_75_3.pdf
Transport InfoProduct name: Bevacizumab
Contact Us

Phone:

630-322-8886

630-322-8887

Email:

[email protected]

Office Locations:

Chicago, IL, USA

San Francisco, CA, USA